Pancreatic Cancer Research

ResearcherUniv Of Massachusetts Med Sch WorcesterActive in the last 2 years

Jason Robert Pitarresi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-9549-4768; OpenAlex author ID A5065125959; NIH RePORTER profile ID 12053426. Sources: OpenAlex.

Their work

Papers
22 (first author 1, last author 2)
Trials
0
Grants
5
Labs led
2
Collaborators
103
Papers, trials and grants by year

2015: 2 papers, 1 grant · 2016: none · 2017: 1 paper · 2018: 2 papers, 1 grant · 2019: 3 papers · 2020: 1 paper · 2021: 1 paper · 2022: 2 papers, 1 grant · 2023: 3 papers · 2024: 3 papers, 1 grant · 2025: 3 papers · 2026: 1 paper, 1 grant

Papers 22

  1. Multiplexed cytokine and antigen mRNA administration generates durable anti-tumor immunity against pancreatic cancer. Co-author DOI 10.1038/s41467-026-74574-z↗
  2. Mitochondrial Ca2+ controls pancreatic cancer growth and metastasis by regulating epithelial cell plasticity. Co-author DOI 10.1016/j.celrep.2025.115627↗
  3. Pancreatic cancer cachexia is mediated by PTHrP-driven disruption of adipose de novo lipogenesis Last author DOI 10.1101/2025.06.03.657464↗
  4. To EMT or Not to EMT: Ablation of Mesenchymal Tumor Cell Lineages Reveals the Essential Role of EMT in Pancreatic Cancer Initiation and Evolution. Last author DOI 10.1158/0008-5472.can-25-1443↗
  5. Senescent cancer-associated fibroblasts in pancreatic adenocarcinoma restrict CD8+ T cell activation and limit responsiveness to immunotherapy in mice. Co-author DOI 10.1038/s41467-024-50441-7↗
  6. Nanoparticle delivery of innate immune agonists combined with senescence-inducing agents promotes T cell control of pancreatic cancer. Co-author DOI 10.1126/scitranslmed.adj9366↗
  7. A Histone Methylation-MAPK Signaling Axis Drives Durable Epithelial-Mesenchymal Transition in Hypoxic Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-22-2945↗
  8. Netrin-1 feedforward mechanism promotes pancreatic cancer liver metastasis via hepatic stellate cell activation, retinoid, and ELF3 signaling. Co-author DOI 10.1016/j.celrep.2023.113369↗
  9. Phase Ib and Expansion Study of Gemcitabine, Nab-Paclitaxel, and Ficlatuzumab in Patients With Metastatic Pancreatic Cancer. Co-author DOI 10.1093/oncolo/oyad002↗
  10. Tumor-Suppressive and Immune-Stimulating Roles of Cholesterol 25-hydroxylase in Pancreatic Cancer Cells. Co-author DOI 10.1158/1541-7786.mcr-22-0602↗
  11. MYC Levels Regulate Metastatic Heterogeneity in Pancreatic Adenocarcinoma. Co-author DOI 10.1158/2159-8290.cd-20-1826↗
  12. STAT3 in tumor fibroblasts promotes an immunosuppressive microenvironment in pancreatic cancer. Co-author DOI 10.26508/lsa.202201460↗
  13. PTHrP Drives Pancreatic Cancer Growth and Metastasis and Reveals a New Therapeutic Vulnerability. Co-author DOI 10.1158/2159-8290.cd-20-1098↗
  14. Pharmacologic Activation of the G Protein-Coupled Estrogen Receptor Inhibits Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.jcmgh.2020.04.016↗
  15. Mechanisms Underlying Metastatic Pancreatic Cancer. Co-author DOI 10.1007/978-3-030-22254-3_1↗
  16. PRRX1 isoforms cooperate with FOXM1 to regulate the DNA damage response in pancreatic cancer cells. First author DOI 10.1038/s41388-019-0725-6↗
  17. Murine models for familial pancreatic cancer: Histopathology, latency and drug sensitivity among cancers of Palb2, Brca1 and Brca2 mutant mouse strains. Co-author DOI 10.1371/journal.pone.0226714↗
  18. Regulation of Epithelial Plasticity Determines Metastatic Organotropism in Pancreatic Cancer. Co-author DOI 10.1016/j.devcel.2018.05.025↗
  19. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer. Co-author DOI 10.1136/gutjnl-2016-311585↗
  20. Generation of a pancreatic cancer model using a Pdx1-Flp recombinase knock-in allele. Co-author DOI 10.1371/journal.pone.0184984↗
  21. Anti-IL-6 and PD-L1 antibody combination therapy reduces tumor progression in murine models of pancreatic cancer Co-author DOI 10.1186/2051-1426-3-s2-p366↗
  22. Single agent BMS-911543 Jak2 inhibitor has distinct inhibitory effects on STAT5 signaling in genetically engineered mice with pancreatic cancer. Co-author DOI 10.18632/oncotarget.6332↗

Grants 5

  1. Uncovering the mechanisms by which CAMK2B loss promotes metastasis and immune suppression in pancreatic cancer R56CA303722↗
  2. Dissecting the oncogenic and pro-metastatic roles of PTHLH-mediated calcium signaling in pancreatic cancer R00CA252153↗
  3. Dissecting the oncogenic and pro-metastatic roles of PTHLH-mediated calcium signaling in pancreatic cancer K99CA252153↗
  4. The role of p120ctn in PDAC epithelial-to-mesenchymal transition and metastasis F32CA221094↗
  5. The Role of Cancer Associated Fibroblasts in Pancreatic Tumor Progression F31CA189757↗

Closest collaborators

The 25 strongest of 103 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ben Z. Stanger · 7 shared papers, 2020–2025 · strength 0.99
  2. Jessica Peura · 4 shared papers, 2024–2025 · strength 0.98
  3. Marcus A. Ruscetti · 4 shared papers, 2024–2026 · strength 0.78
  4. Nikita Bhalerao · 3 shared papers, 2025–2026 · strength 0.61
  5. Anil K. Rustgi · 4 shared papers, 2019–2023 · strength 0.57
  6. Robert J. Norgard · 4 shared papers, 2020–2025 · strength 0.50
  7. Jinyang Li · 4 shared papers, 2020–2023 · strength 0.45
  8. Anil K. Rustgi · 3 shared papers, 2018–2025 · strength 0.39
  9. Loretah Chibaya · 2 shared papers, 2024–2026 · strength 0.38
  10. Chaitanya Naimesh Parikh · 2 shared papers, 2024–2026 · strength 0.38
  11. Michael C. Ostrowski · 5 shared papers, 2015–2022 · strength 0.33
  12. Basil S. Bakir · 3 shared papers, 2018–2023 · strength 0.29
  13. Igor A. Astsaturov · 2 shared papers, 2023 · strength 0.28
  14. Kensuke Suzuki · 3 shared papers, 2018–2021 · strength 0.27
  15. Gregory B. Lesinski · 4 shared papers, 2015–2022 · strength 0.27
  16. Thomas Ludwig · 4 shared papers, 2015–2019 · strength 0.25
  17. Thomas A. Mace · 4 shared papers, 2015–2019 · strength 0.25
  18. Teresa A Zimmers · 3 shared papers, 2015–2022 · strength 0.23
  19. Brian C. Lewis · 1 shared paper, 2026 · strength 0.22
  20. Jillian Weissenrieder · 1 shared paper, 2025 · strength 0.21
  21. James Kevin FOSKETT · 1 shared paper, 2025 · strength 0.21
  22. Benoît Marchand · 2 shared papers, 2019–2021 · strength 0.21
  23. Faiyaz Notta · 2 shared papers, 2021–2022 · strength 0.20
  24. Michael Anthony Hollingsworth · 1 shared paper, 2025 · strength 0.18
  25. Paul M. Grandgenett · 1 shared paper, 2025 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.